“Indazole Analogue 16 as Potential Therapy for Castration-Resistant Prostate Cancer: Inhibition of Androgen Receptor N-Terminal Domain”

https://pubmed.ncbi.nlm.nih.gov/38116409

A new small molecule, indazole analogue 16, has shown potential as a starting point for developing a therapy for castration-resistant prostate cancer, as it inhibits the androgen receptor N-terminal domain and has favorable physical and chemical properties.